Mithracin
Mithracin
Mithracin (pronunciation: mi-THRA-cin), also known as plicamycin, is a chemotherapeutic drug used in the treatment of various types of cancer, including testicular cancer and certain types of bone cancer.
Etymology
The term "Mithracin" is derived from the genus name of the bacteria from which it was first isolated, Streptomyces plicatus. The suffix "-cin" is commonly used in the names of antibiotics and chemotherapeutic drugs.
Usage
Mithracin is primarily used in the treatment of testicular cancer and bone cancer. It works by binding to DNA and inhibiting RNA synthesis, thereby preventing the growth and multiplication of cancer cells. Mithracin is usually administered intravenously.
Side Effects
Common side effects of Mithracin include nausea, vomiting, and loss of appetite. More serious side effects can include kidney damage, abnormal bleeding, and changes in bone marrow function.
Related Terms
- Chemotherapy: The use of drugs to treat diseases such as cancer.
- DNA: The molecule that carries genetic information in all living organisms.
- RNA: A molecule similar to DNA that plays a crucial role in protein synthesis and other chemical activities of the cell.
- Bone marrow: The soft, spongy tissue in the center of the bones that produces blood cells.
See Also
External links
- Medical encyclopedia article on Mithracin
- Wikipedia's article - Mithracin
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski